Johan Kördel is interviewed about Sound Bioventures and its Investment Strategy by BioStock

Johan Kördel - Sound Bioventures

To be able to contribute to the development of new drugs is very exciting! I am passionate about helping people to a better life – says Johan Kördel

Sound Bioventures strategy is to invest in private clinical stage therapeutics companies. In the interview Johan expands on the opportunity to create private spin-outs from public companies, that in some cases trade for less than their cash, and raise money from venture funds to allow clinical programs to advance. This opportunity has arisen with the suppressed public valuations the biotech sector has seen the last year. Read the full interview below.

About BioStock

BioStock is Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector. BioStock’s content is aimed at investors and representatives of companies and organizations in biotechnology, medical technology, diagnostics and drug development. BioStock’s daily news updates are followed by a majority of decision-makers at management level in Nordic life science.

Subscribe

* indicates required

Artax Biopharma Expands Company’s Scientific Advisory Board and Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases

Cambridge, MA, November 15, 2022 Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company is strengthening its Scientific Advisory Board (SAB) with the appointments of James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D. Artax Biopharma has an ...